In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Dutch Decision Invalidates Truvada SPC

Basic Patent Did Not Identify Emtricitabine

Executive Summary

Gilead’s Truvada is not entitled to an SPC in the Netherlands because the patent on which the SPC application referred mentions only one of the two active ingredients in the combination antiretroviral.

You may also be interested in...



UK Rejects Truvada SPC Again

A supplementary protection certificate for Gilead’s Truvada combination antiviral is invalid because emtricitabine is not disclosed in the relevant patent, a UK appeals court has confirmed. But questions around the correct legal test remain unanswered.

Duo Dance Two-Step To Cut Irish Truvada Term

Both steps of a test laid down by the Court of Justice for the European Union for invalidating supplementary protection certificates for combination products were satisfied by Mylan and Teva in an Irish dispute over protection for Gilead’s Truvada combination antiretroviral.

UK’s ruling on Truvada marks ‘major first step’

A court decision to invalidate Gilead’s UK supplementary protection certificate (SPC) on Truvada (tenofovir disoproxil/emtricitabine) is a “major first step in ensuring timely and appropriate generic competition” to the combination antiretroviral, as well as “a step forward in ensuring certainty and quality of the patent and SPC systems” in Europe, according to Medicines for Europe.

Topics

UsernamePublicRestriction

Register

SC027449

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel